152 results about "Lung alveolus" patented technology

A bronchoalveolar lavage instillation / aspiration system which includes (i) a needleless bronchoalveolar lavage instillation / aspiration device with a barrel member including a barrel lumen having a distal aperture and a self-sealing member configured for maintaining a fluid-disruptable, resealable barrier to the distal aperture; and (ii) a catheter assembly configured to provide a patent path of fluid communication between the instillation / aspiration device and a patient bronchial passage, where the catheter includes a wedging structure configured to engage a patient bronchial passage. In another aspect, embodiments of the present invention may include one or more methods of making and using a system or component described herein.

Method for providing ventilatory settings with regard to the airway pressure levels of an artificial ventilator, the artificial ventilator is connected to a lung, including the steps of obtaining data samples of a gas concentration of the expired gas over a single breath; selecting a plurality of data samples from the obtained data samples; calculating a tracing value being sensitive to changes of alveolar dead space on the basis of the selected data samples; repeating steps a), b) and c) for obtaining a plurality of tracing values; and changing at least one airway pressure level of the artificial ventilator, wherein from an observation of a resulting course of the plurality of calculated tracing values an airway pressure level at which alveolar opening or lung overdistension or lung open condition or alveolar closing occurs is detected. Apparatus for providing ventilatory settings with regard to the airway pressure levels of an artificial ventilator is also disclosed.

The invention relates to a treatment quality management method of a breathing machine. The method comprises: step one, monitoring flowing speed and waveform information of a pipe of a breathing machine; step two, monitoring pressure and waveform information in the pipe of the breathing machine; step three, monitoring oxygen concentration information in an oxygen channel and / or breathing machine pipe; step four, monitoring oxygen flow information in the oxygen channel and sending the information to a cloud and a monitoring terminal; step five, monitoring blood oxygen saturation and pulse rate information in blood of a breathing machine user and sending the information to the cloud and the monitoring terminal; step six, monitoring CO2 pressure dividing information in alveolar of the breathing machine user or a CO2 waveform of an exhalation end in a breathing machine pipe line and sending the monitored information to the cloud and the monitoring terminal; and step seven, monitoring comparison of the terminal and a preset threshold value and determining whether treatment of the breathing machine is normal. With the method, the overall progress is improved based on real-time monitoring of feedback of equipment data and patient data.

Relating to the fields of biotechnologies and gene therapy, the invention provides application of a gene modified mesenchymal stem cell in pulmonary fibrosis treatment. The gene modified mesenchymal stem cells are obtained through: in-vitro isolated culture and amplification of a mesenchymal stem cell (MSC) deriving from bone marrow and an umbilical cord, and recombinant adenovirus Ad-HGF mediated in-vitro modification of the MSC by a hepatocyte growth factor (HGF). By transplanting the gene modified MSC to a C57 mouse to intervene in radiation induced lung injury and fibrosis, exudation of a plurality proteins including albumin, IgM and the like from an alveolar space can be reduced, local inflammatory responses of the lung can be alleviated, and expression of TNF-alpha, soluble ICAM-1 and multiple factors is inhibited, expression of the profibrotic factor TGF-beta, the collagen gene col1 alpha 1 and col 3 alpha 1 can be inhibited, and pulmonary tissue collagen fiber deposition is reduced. The expression results of endogenous HGF and its receptor cmet show that endogenous HGF expression can be induced and endogenous MSC can home to injured parts. Therefore, the employment of HGF modified MSC in treatment of lung injury and fibrosis brought by various pathogenic causes is of great significance.

The present invention relates to a method of predicting the risk of a subject developing a cardiovascular event, comprising determining the presence of a biomarker that is indicative of the risk of developing a cardiovascular event in exosomes from the subject. The exosomes are suitably isolated from a body fluid selected from serum, plasma, blood, urine, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, synovial fluid, breast milk, saliva, in particular serum. The biomarker is selected from the proteins Vitronectin, Serpin F2, CD14, Cystatin C, Plasminogen, Nidogen 2 or any combination of two or more of these proteins.

The invention discloses novel coronavirus 2019-nCoV fluorescent RPA detection primers, a probe, a kit and a method. The kit comprises novel coronavirus 2019-nCoV specific primers shown in SEQ ID NO. 1-2 and a probe shown in SEQ ID NO. 3. According to the invention, the existence of the novel coronavirus 2019-nCoV ORF1ab gene and the internal reference gene RNase P is simultaneously detected by adopting a single-tube double-fluorescence channel, and the existence of the novel coronavirus 2019-nCoV RNA in pulmonary alveolar lavage fluid, nasal swab, pharyngeal swab, sputum and other samples canbe detected. The method is short in detection time and suitable for clinical and bedside virus nucleic acid rapid screening, the kit has extremely high sensitivity and specificity, an internal reference gene is added into the detection system, and quality monitoring is performed on the extraction and amplification process of the sample according to the detection result of the internal reference gene.

The invention relates to ink for releasing negative ions, which belongs to novel healthy environmental-friendly cultural goods for releasing negative ions and can permanently release the negative ions. The number of the released negative ions is more than 1000 / cm. The ink has the efficacy of removing harmful gases and peculiar smell, purifying air, resisting bacteria and inhibiting bacteria, radiating far infrared rays and resisting electromagnetic wave radiation and can improve the secretory function of the alveolus and the ventilation and the air exchange of the lung, improve the microcirculation, strengthen the immunity of a human body and resisting the bacteria, thereby being beneficial to the health and having better health care function. The developed and researched health environmental-friendly ink for releasing negative ions has higher scientific and economic values and important realistic meaning.

The invention belongs to the fields of cell biology and tumor tissue engineering materials and provides a three-dimensional tumor model decellularization porous scaffold, a construction method and application thereof. The whole pig lung scaffold is prefrozen, a uniform part without obvious bronchi is selected and sliced, purified water and PBS are added for cleaning until no blood streak is formed, removing cells with sodium dodecyl sulfate and TritonX-100, and freezing, drying and chemical crosslinking methods are adopted, so that a crosslinked decellularization pig lung three-dimensional tumor model scaffold is obtained. The three-dimensional tumor model decellularization porous scaffold provided by the invention has the advantages that decellularization matrix sourced from pig lung tissues is taken as a scaffold material for constructing a tumor model, on the basis of effectively removing cell components, a pulmonary alveolus-bronchus structural vein network is reserved as soon as possible, a natural extracellular matrix microenvironment can be simulated, and cell adhesion, growth and proliferation are facilitated. The in vitro constructed three-dimensional tumor model after cells are inoculated has a tissue structure closer to an in vivo tissue and is applicable to screening study of anticancer drugs.

Proposed is a Pulse Transit Time, PTT, measurement concept wherein a forced oscillation technique, FOT, is used to determine a pulse arrival time at alveoli of the lungs of a patient.

Method for gentle separation of viable sporadic cells from body fluids such as blood, from malignant effusions, bronchoalveolar lavage fluid, peritoneal lavage fluid and amniotic fluid, based on a filter membrane which is in an intimate contact with an absorbent material. Using the present method it is possible to isolate for example circulating and disseminated tumor cells, endometrial cells and circulating trophoblast cells, allowing subsequent detection, quantification, characterization and especially culturing of said cells. An apparatus for carrying out the method is further disclosed.

The invention relates to a breathing machine man-machine asynchronous classification method and system, a terminal and a storage medium. The method comprises the steps: collecting the multi-channel breathing data of a simulated flow channel, a tidal volume channel, airway pressure, alveolar pressure, pleural cavity internal pressure, cardiac pressure, a corrugated pipe position channel and the like under a man-machine asynchronous event simulated by a simulated lung and a breathing machine; carrying out replacement deviation index (PDI) feature extraction on the respiration data, and labeling the respiration data according to the extracted PDI features; inputting the labeled respiration data into a network model for training to obtain a trained man-machine asynchronous classification model; and classifying the breathing machine man-machine asynchronous events through the trained man-machine asynchronous classification model. According to the embodiment of the invention, the acquired respiration data is small in interference and convenient to acquire, difference analysis of the respiration data of the adjacent channels is carried out by using the PDI features, and the accuracy of man-machine asynchronous classification is improved.

The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.

The invention discloses an allergen protein BA2 of Periplaneta americana and an expression method thereof. The expression method comprises the following steps: (1) extracting the RNAs of Periplaneta americana, subjecting the RNAs to inverse transcription to obtain cDNAs and carrying out PCR amplification with the cDNAs as a template so as to obtain a coding gene fragment of the allergen protein ofPeriplaneta americana; and (2) cloning an allergen gene into a prokaryotic expression vector to construct recombinant expression plasmid pET28a(+)-BA2, transferring the recombinant expression plasmidinto the host bacterium Escherichia coli BL21, inducing the expression of the recombinant expression plasmid with IPTG and carrying out purifying by using affinity chromatography so as to obtain therecombinant allergen protein BA2 of Periplaneta americana. The results of pharmacological experiments show that the allergen protein BA2 can obviously increase the IgE content (wherein P is less than0.05) of mouse serum, substantially increase the contents of IL-4, IL-5 and IL-13 inflammatory factors in mouse bronchoalveolar lavage fluid and mouse splenocyte supernatant, and result in obvious pathological changes of mouse lung tissue. The method provided by the invention can prepare the allergen protein with high purity and provides referential bases for subsequent research on the allergens of Periplaneta americana and potential allergen substances in other animals.

The invention discloses a lung tissue model for a puncture operation experiment. The modal comprises a mounting chassis, an optical positioning unit, a lung tissue unit, a simulated breathing unit anda data acquisition and control unit; a pulmonary alveolar biomimetic model, a tumor biomimetic model and an optical positioning marker are integrated by the lung tissue model, so respiratory movementof the lung can be simulated on the basis of real data; the lung tissue model is particularly suitable for puncture operation experiments based on optical positioning navigation, and the real environment is greatly restored.

The invention provides a method for evaluating lung injury caused by nanoparticles based on organ-on-a-chip technology. A chip is mainly prepared by bonding and sealing an upper PDMS layer and a lowerPDMS layer and comprises a matrix inlet pool, two cell inlet pools, a waste liquid pool, a cell culture chamber and a matrix chamber. The chip is vertically inoculated with vascular endothelial cellsand alveolar epithelial cells separately, and culture is carried out for a certain period of time so as to form a lung air-blood barrier. Nanometers are added into an alveolar epithelial cell culturechamber, and monocytes are added into a vascular endothelial cell culture chamber in the manner of perfusion to simulate monocytes in the circulating blood of people, so an in-vitro nanoparticle lunginjury evaluation model is established. The nanoparticle lung injury evaluation model based on the chip can simulate the injury of the nanoparticles to the lung air-blood barrier, monitors destroy tothe integrity of the barrier in real time, realizes observation of the responses of two types of cells of the air-blood barrier, and traces the motion of the monocytes in real time.

The invention discloses an alveolar ventilation monitoring system based on a non-invasive ventilator and a control method. The system comprises a breathing machine body, a user breathing end, an MCU and a display screen, wherein an air pressure electric adjusting module is arranged in the breathing machine body, and a differential pressure type flow sensor and a first pressure sensor are arrangedat the output end of the air pressure electric adjusting module; the air pressure electric adjusting module, the differential pressure type flow sensor and the first pressure sensor are all electrically connected with the MCU; and the differential pressure type flow sensor and the first pressure sensor acquire the gas flow and pressure output by the air pressure electric adjusting module respectively, and the MCU acquires detection data of the differential pressure type flow sensor and the first pressure sensor and displays the detection data through the display screen. The breathing state ofa patient can be monitored, the airflow pressure is intelligently compensated and adjusted according to the breathing state of the patient, the patient is helped to keep the optimal breathing state, and a powerful guarantee is provided for lung treatment of the patient.

The invention discloses a method for preparing a pneumonia rat model and a model evaluation method, and belongs to the technical field of biology. The method for establishing the pneumonia rat model is non-invasive and safe to rats, does not damage other organs of rats in the whole process, and effectively avoids the death of the rats. Besides, the method has simple operation and high success rate. According to the pneumonia rat model established by the method, pseudomonas aeruginosa in bronchoalveolar lavage fluid is obviously increased, inflammatory factors IL-4 and TNF-alpha are obviously increased, the level of adhesion factor IFN-gamma is obviously reduced, and the number of leukocytes is obviously increased. Meanwhile, the lung index is also obviously increased, which indicates thatthe model is established well.

A method for generating progeny of an African swine fever (ASF) virus includes providing an isolated or purified fetal porcine lung alveolar macrophage cell capable of replicating the ASF virus, wherein the cell is cultured for at least 5 passages; exposing the cell to the ASF virus; and allowing the ASF virus to replicate in the cell; thereby generating progeny of the ASF virus.

The invention discloses a balloon catheter assembly for bronchoscope. The balloon catheter assembly comprises a hairbrush for brush biopsy, an inner catheter used for conveying lavage fluid, medicinefluid and the hairbrush from the external portion to a target bronchus, and an outer catheter which sleeves the inner catheter and is provided with a balloon. The outer catheter is in sealing connection with the inner catheter so that a sealed space can be formed between the inner catheter and the outer catheter, and the balloon can be inflated, wherein the outer catheter is communicated with an air inflation pipe. The inner catheter is provided with a lavage channel, a medicine injection channel and a hairbrush send-in channel, wherein two ends of the lavage channel are penetrating, the lavage channel is used for conveying the lavage fluid, the medicine injection channel is used for conveying the medicine fluid, and the hairbrush send-in channel is used for conveying the hairbrush. An anti-polluting plug used for blockwork is arranged at the outlet end of the hairbrush send-in channel. The balloon catheter assembly is used for bronchoalveolar lavage, medicine injection and hairbrush biopsy of the bronchus, improves the treatment efficiency and reduces the economical burdens of patients.

This invention provides pertains to the discovery that that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and / or reverse the injury caused by nicotine.

A system and method for determining a potential lung recruitment value for a patient that includes during an applied first positive end expiratory pressure (PEEP) to the lungs of the patient, measuring a first end expiratory lung impedance (EELZ) of the lungs at the first PEEP; during an applied second PEEP, measuring a second EELZ at the second PEEP, determining a change in EELZ between the firstPEEP and the second PEEP, determining a first chord-compliance of the lungs from pixels of a first electrical impedance tomography (EIT) image of the patient at the first PEEP, determining a second chord-compliance from a second EIT image of the patient at the second PEEP, determining a first index representing the change in EELZ, determining a second index representing a change in compliance, and based on the first index and the second index, determining a potential lung recruitment value for the patient.

The invention provides a culture medium and method for inducing human pluripotent stem cells to be differentiated into alveolar cells or alveolar organs, and particularly relates to a culture medium and method for inducing the human pluripotent stem cells to be differentiated into lung precursor cells or alveolar cells by using a small molecule activator / inhibitor. The cells obtained by induced differentiation express typical lung precursor cells and alveolar cell biomarkers, and a three-dimensional human alveolar organ has an alveolar-like blister structure and can be used as a material for toxicological research, drug screening and lung disease research.

The invention discloses a reversion pulmonary fibrosis nano preparation and a preparation method thereof, and relates to a synthetic E5 and polypeptide Z modified nano preparation and a carrier thereof. The nano preparation is capable of, through E5 targeted circulation fibrocyte CXCR4, CCR2 and CCR7 acceptors, reaching a pulmonary fibrosis injured part in a fixed point, and avoiding from being packaged and cleared by in-vivo macrophages and proteins; and through polypeptide Z, specific-targeting alveolar epithelial cells II of a high-expression integrin acceptor AlphavBeta6, and efficiently targeting and delivering the nano preparation. The nano preparation contains an anti-oxidant and / or a fibroblast activation inhibitor. A purpose of reversing pulmonary fibrosis is achieved by controlling an alveolar epithelial cell II oxidative stress level and inhibiting fibroblast activation double-channel control.

An imitating lung device includes a first liquid accommodating layer, a first elastic membrane, an airway layer, a second elastic membrane and a second liquid accommodating layer. A first liquid chamber is formed in an inner surface portion of the first liquid accommodating layer. The airway layer includes a plurality of air channels and a plurality of imitating alveolar regions. The imitating alveolar regions are communicated with the air channels. The air channels simulate a branched structure of the 15th generation to the 19th generation of a human lung, and the imitating alveolar regions simulate a branched structure of the 20th generation to the 23th generation of a human lung. A second liquid chamber is formed in an inner surface portion of the second liquid accommodating layer.

The invention particularly discloses application of mesenchymal stem cells in regulation and control of monocytes of viral infection patients, relates to the technical field of biological medicines, and particularly relates to application in regulation and control of monocyte gene expression and monocyte toxic gene expression of the viral infection patients. According to the application, a mesenchymal stem cell preparation is brought into a conventional treatment scheme to perform combined treatment on the viral infection patients in an MSC treatment group, so that effective regulation and control of the monocyte gene expression and the monocyte toxic gene expression of the viral infection patients are realized, and as a result, the in-vivo excessive immune response of the patients can beeffectively inhibited in time, the in-vivo alveolar function of the patients is protected, and the damage to the lungs and the organs of the whole body of the viral infection patients is reduced. Therefore, the mesenchymal stem cells can effectively treat complications of the viral infection patients by virtue of an immune regulation mechanism, an anti-inflammatory effect and the characteristic ofrepairing damaged tissues.

The invention discloses a method for pathologically fixing an experimental animal lung, which comprises the following steps of: (1) filling a fixing liquid, namely, suspending a filling container filled with the fixing liquid onto an isolated animal lung, inserting the liquid outlet end of a filling tube connected with the filling container into trachea of the isolated animal lung, and filling the fixing liquid into pulmonary alveoli of the animal lung by utilizing the hydrostatic pressure formed by the height difference between the liquid surface of the fixing liquid and the horizontal surface of the animal lung so as to naturally extend the animal lung; and (2) soaking the fixing liquid, namely, completely soaking the animal lung obtained in the step (1) into the fixing liquid to be fixed. The method is convenient to operate, low in cost and fast in fixing; the method can be controlled in a normalizing manner; and the method can enable the animal lung to be completely, uniformly and naturally filled, so that natural shapes of lung tissues is favorably stored and the need of observing pathological change of small blood vessels and small tracheas of the lung is met.

A bi-lateral endobronchial suctioning device includes actuating and articulating components that allow a provider to accurately suction both right and left bronchi as well as the trachea in a controlled and safe manner. A control mechanism is used to manipulate the actuating components in tubes forming a suction catheter to flex the tip of the bi-lateral endobronchial suctioning device to the left and to the right when the device is inserted through an endotracheal tube or other similar device, to enable directional control of a catheter for suctioning the lungs or trachea. The device further includes a bronchoalveolar lavage (BAL) port allowing sterile saline or other liquids or fluids to travel down the catheter lumen to assist with breaking up thick secretions which collect in the airways.

The invention discloses an application of iodine in preparation of a medicine for preventing and treating respiratory tract infectious diseases and a method for preparing iodine-containing aerosol with low particle size. According to the invention, iodine is dissolved in pure water and an oily solvent to respectively prepare two iodine solution atomizing agents, and the two iodine solution atomizing agents are atomized into iodine-containing aerosol by an atomizer to be inhaled into the respiratory tract, so that pathogens are quickly and efficiently killed, and the iodine-containing aerosol becomes the only specific medicine for treating respiratory virus infection lacking effective treatment medicines; and more effective and convenient treatment medicines are provided for infection of respiratory bacteria, mycoplasmas, fungi and the like. The method is mainly characterized in that iodine is prepared into a low-concentration iodine solution and atomized into iodine-containing aerosol, so that the density of iodine is greatly reduced, the irritation is greatly reduced, and iodine molecules enter the respiratory tract to kill pathogens; the iodine-containing aerosol with low particle size can reach pulmonary alveoli to directly screen and kill viruses in the pulmonary alveoli, so that critical and severe pulmonary infection patients can be quickly out of danger, and mild diseases can be quickly cured.

The invention relates to a lung tissue single-channel fixing instrument and overcomes the defects that existing lung tissue fixing is low in speed, fixing liquid immersion efficiency is affected, the exposure time of lung tissues is excessively long, and the experiment result is affected. The lung tissue single-channel fixing instrument comprises a fixing body, the fixing body is internally provided with a containing cavity for containing fixing liquid, the fixing body is provided with an opening communicated with the containing cavity, a sealing cover is arranged at the opening, the side wall of the fixing body is provided with a side channel communicated with the containing cavity, and the side channel is internally provided with an air pulling core. As the air pulling core moves outwards, the volume of the containing cavity is increased, so that the pressure intensity in the containing cavity is lowered, a negative pressure state is formed, in the negative pressure environment, air in the lung tissues is discharged rapidly, under the elasticity of the lung tissues, the fixing liquid is immersed into pulmonary alveoli rapidly, and the pulmonary alveoli recovers to the original shape, so that lung tissue cells are integrally fixed, and subsequent immunohistochemistry and pathological analysis are facilitated.

The invention relates to the technical field of medicine, in particular to a lung knock injury animal model construction method which can truly reflect physical parameters related to explosion and a complex action process generated by interaction of the physical parameters and can achieve quantitative evaluation on the range, grade and severity of lung injury. A lung knock injury animal model constructed by the method verifies that the resveratrol has a relatively good curative effect in treating lung knock injury, has the advantages of wide source, safety, difficulty in generating drug resistance and the like, and can reduce lung tissue bleeding, alveolar septum rupture and inflammatory cell infiltration of a lung knock injury rat and relieve the lung tissue edema.